

TWO STEROIDAL ALKALOIDS FROM *VERATRUM VIRIDE*

KHALID A. EL SAYED,\* JAMES D. MCCHESENEY,† AHMED F. HALIM, AHMED M. ZAGHLOUL and MARKUS VOEHLER‡

Pharmacognosy Department, Faculty of Pharmacy, Mansoura University, Mansoura 35511, Egypt; †The Research Institute of Pharmaceutical Sciences and Department of Pharmacognosy, School of Pharmacy, University of Mississippi, MS 38677, U.S.A.;


‡Department of Chemistry, Vanderbilt University, Nashville, TN 37235, U.S.A.

(Received in revised form 14 September 1994)

**Key Word Index**—*Veratrum viride*; Liliaceae; roots; rhizomes; steroidal alkaloids; rubivirine; veramivirine.**Abstract**—A phytochemical study of the roots and rhizomes of *Veratrum viride* led to the isolation of the two new steroidal alkaloids, rubivirine, identified as 12 $\beta$ -hydroxyisorubijervine, and veramivirine, identified as 12 $\beta$ -hydroxyveramiline. Structural elucidation of the two compounds was aided by 2D-NMR spectral analyses.

## INTRODUCTION

The roots and rhizomes of *Veratrum viride* have been extensively studied for their hypotensive [1] and cytotoxic [2] activities and in the therapy of myasthenia gravis [3]. About 25 steroidal alkaloids have been isolated from this species so far [4]. The isolation of the known alkaloids, veramarine, zygadenine, angeloyl-zygadenine and 15-*O*-2-methylbutyrylgermine, as well as 1 $\alpha$ ,3 $\beta$ -dihydroxy 5 $\alpha$ -jervanin-12-en-11-one, a new jervanine alkaloid, has been reported [5]. Further phytochemical work on this species has led to the isolation of two new steroidal alkaloids, rubivirine (1) and veramivirine (2).



#	Compound	R <sub>1</sub>	R <sub>2</sub>
1	Rubivirine	$\beta$ -OH	CH <sub>2</sub> OH
3	Rubijervine	$\alpha$ -OH	CH <sub>3</sub>
4	Isorubijervine	H	CH <sub>2</sub> OH
5	Epirubijervine	$\beta$ -OH	CH <sub>3</sub>
6	Solanidine	H	CH <sub>3</sub>

## RESULTS AND DISCUSSION

The alkaloid-containing fractions were separated by a combination of flash chromatography on silica gel, preparative TLC and fractional recrystallization to give rubivirine (1) and veramivirine (2). Both compounds gave positive Dragendorff, iodoplatinate and Mayer tests, indicating their alkaloidal nature. They also gave positive Liebermann-Burchard and Salkowski tests, indicating their steroidal nature.

Rubivirine (1) was recrystallized from methanol to give needles. Thermospray-LC-MS analysis displayed a  $[M + H]^+$  at  $m/z$  430 suggesting the molecular formula C<sub>27</sub>H<sub>43</sub>NO<sub>3</sub>. The methyl singlet which absorbed at  $\delta$  0.92 in the <sup>1</sup>H NMR (Table 1) is correlated with the methyl carbon at  $\delta$  19.2 and was assigned to the 19-methyl group. On the other hand, the two methyl doublets at  $\delta$  0.87 ( $J = 6.2$  Hz) and 1.06 ( $J = 7.4$  Hz) are corre-

lated with the two methyl carbons at  $\delta$  18.9 and 19.4, and ascribed to the 21- and 27-methyl groups. These assignments revealed the 22,26-epimincholestane skeleton of this alkaloid [6]. The  $\alpha$ -axial proton H-12 resonating at  $\delta$  3.30 as a  $dd$  ( $J = 7.7$  and 4.3 Hz) is correlated with a methine carbon at  $\delta$  69.0 and assigned to C-12 on the basis of HETCOR. The proton signals, which resonated at  $\delta$  3.97 (1H,  $d$ ,  $J = 12.2$  Hz) and 3.51 (1H,  $d$ ,  $J = 12.0$  Hz), and correlated with the oxygenated methylene carbon at 62.4, were assigned to a C-18 hydroxymethyl group. Confirmation of the position of the hydroxymethyl group was achieved by comparison of the <sup>13</sup>C NMR spectra (Table 2) of 1 with that reported for solanidine (6), which is 12,18-dideoxyrubivirine [7]. The hydroxyl group substitution at C-18 caused significant shifts at C-13 (+4.9), C-17 (−5.9) as well as C-18 (+45.4). It also caused a significant shift at C-12 (−2.9) as compared with rubijervine (3), which is 12 $\alpha$ -hydroxysolanidine [5]. The equatorial proton H-26 absorbed at  $\delta$  2.91 as a  $dd$  ( $J = 9.1$  and 2 Hz) and is geminally coupled to the axial H-26 proton which resonated

\*Author to whom correspondence should be addressed.

Table 1.  $^1\text{H}$  NMR spectral data of the isolated alkaloids and related compounds (300 MHz, in  $\text{CDCl}_3$ - $\text{CD}_3\text{OD}$ , 1:1)


H	3	4*	1	2†
1eq	1.81 <i>ddd</i> (13.5, 3.7, 3.1)	1.81 <i>m</i>	1.66 <i>m</i>	1.82 <i>m</i>
1ax	1.09 <i>ddd</i> (13, 7.8, 3.3)	1.11 <i>m</i>	0.98 <i>m</i>	1.06 <i>m</i>
2eq	1.77 <i>m</i>	1.68 <i>m</i>	1.72 <i>m</i>	1.75 <i>m</i>
2ax	1.55 <i>m</i>	1.05 <i>m</i>	1.12 <i>m</i>	1.45 <i>m</i>
3	3.41 <i>dddd</i> (15.4, 10.5, 5.6, 5.3)	3.50 <i>m</i>	3.46 <i>m</i>	3.52 <i>m</i>
4eq	2.25 <i>dd</i> (13.5, 3.8)	2.28 <i>ddd</i> (13.5, 5.6, 1.5)	2.12 <i>m</i>	2.24 <i>m</i>
4ax	2.18 <i>ddd</i> (13.6, 8.2, 1.9)	2.22 <i>ddd</i> (13.5, 9.5, 1.4)	1.97 <i>m</i>	2.21 <i>m</i>
6	5.33 <i>dd</i> (4.1, 1.1)	5.33 <i>br d</i> (4.9)	5.33 <i>br s</i>	5.34 <i>br s</i>
7eq	1.98 <i>dt</i> (13.4, 4.9)	2.06 <i>dt</i> (13.5, 2.3)	1.92 <i>m</i>	1.95 <i>m</i>
7ax	~ 1.53 <i>m</i>	~ 1.57 <i>m</i>	~ 1.51	1.82 <i>m</i>
8	~ 1.62 <i>m</i>	~ 1.58 <i>m</i>	~ 1.60	1.56 <i>m</i>
9	~ 1.72 <i>m</i>	~ 1.04 <i>m</i>	~ 1.01	0.97 <i>m</i>
11eq	~ 1.67	1.49 <i>m</i>	1.55 <i>m</i>	1.62 <i>m</i>
11ax	~ 0.87	1.46 <i>m</i>	0.89	1.42 <i>m</i>
12eq	3.69 <i>dd</i> (1.1, 1)	~ 1.75	—	—
12ax	—	~ 1.03	3.30 <i>dd</i> (7.7, 4.3)	4.1 <i>dd</i> (8.8, 3.6)
14	1.34 <i>m</i>	1.30 <i>m</i>	1.33 <i>m</i>	1.43 <i>m</i>
15eq	1.64 <i>m</i>	1.76 <i>m</i>	~ 1.30	1.49 <i>m</i>
15ax	1.18 <i>m</i>	1.29 <i>m</i>	~ 1.25	1.41 <i>m</i>
16	2.66 <i>ddd</i> (10.5, 10, 3.2)	2.76 <i>ddd</i> (8.3, 8.2, 4.5)	1.59 <i>m</i>	1.63 <i>m</i>
17	2.27 <i>dd</i> (10.7, 10.5)	~ 1.66	1.23 <i>m</i>	1.43 <i>m</i>
18	0.88 3H <i>s</i>	3.86 <i>d</i> (12.1)	3.97 <i>d</i> (12.2)	0.71 3H <i>s</i>
	—	3.46 <i>d</i> (12.2)	3.51 <i>d</i> (12)	—
19-H <sub>3</sub>	1.01 3H <i>s</i>	1.03 3H <i>s</i>	1.04 <i>s</i>	0.98 3H <i>s</i>
20	1.61 <i>m</i>	1.89 <i>m</i>	1.82	1.89 <i>m</i>
21-H <sub>3</sub>	0.94 3H <i>d</i> (5.9)	0.84 3H <i>d</i> (6.2)	0.87 <i>d</i> (6.2)	1.01 <i>d</i> (7.1)
22	1.59 <i>m</i>	1.61 <i>m</i>	1.75 <i>m</i>	2.78 <i>m</i>
23eq	1.63 <i>m</i>	1.63 <i>m</i>	1.62 <i>m</i>	1.71 <i>m</i>
23ax	1.17 <i>m</i>	1.56 <i>m</i>	1.53	1.34 <i>m</i>
24eq	~ 1.67 <i>m</i>	~ 1.78 <i>m</i>	~ 1.70 <i>m</i>	1.63 <i>m</i>
24ax	~ 1.60 <i>m</i>	~ 1.46 <i>m</i>	~ 1.60 <i>m</i>	1.62 <i>m</i>
25	1.69 <i>m</i>	1.84 <i>m</i>	1.81 <i>m</i>	1.91 <i>m</i>
26eq	2.91 <i>dd</i> (10.6, 3)	2.90 <i>dd</i> (9.1, 2)	2.91 <i>dd</i> (9.8, 2)	2.89 <i>dd</i> (9.1, 2)
26ax	1.46 <i>dd</i> (11.1, 3.3)	1.56 <i>m</i>	~ 1.56 <i>m</i>	1.58 <i>m</i>
27-H <sub>3</sub>	0.86 3H <i>d</i> (6.7)	1.01 3H <i>d</i> (6.7)	1.03 <i>d</i> (6.3)	1.06 <i>d</i> (7.4)

\*In  $\text{CDCl}_3$ .†In  $\text{CDCl}_3$ , 500 MHz.

at  $\delta$  1.46. Both protons were correlated to the same methylene carbon at  $\delta$  60.4. Interestingly, the deshielded methine carbon at  $\delta$  74.4 correlated with a proton which resonated at  $\delta$  1.75 and was assigned to H-22.

Isorubijervine (4) and epirubijervine (5) are suggested to be intermediates in the biogenesis of the C-nor-D-homosteroidal *Veratrum* alkaloids [8]. The proposed pathway is acetate  $\rightarrow$  mevalonate  $\rightarrow$  cholesterol  $\rightarrow$  solanidanes (probably isorubijervine and/or epirubijervine)  $\rightarrow$  C-nor-D-homosteroidal alkaloids [9]. Rubivirine is presumably another intermediary phase in the process of *Veratrum* alkaloid biogenesis.

Veramivirine (2) was recrystallized from methanol to give needles. Thermospray-LC-MS analysis displayed a  $[\text{M} + \text{H}]^+$  at  $m/z$  416 suggesting the molecular formula  $\text{C}_{27}\text{H}_{45}\text{NO}_2$ . The  $^1\text{H}$  and  $^{13}\text{C}$  NMR data (Tables 1 and 2) showed a close resemblance to those of veramiline (7) and veramiline 3- $\beta$ -D-glucopyranoside (8), 22,26-epimincholestane alkaloids previously isolated from other *Veratrum* species [10–12].



#	Compound	R <sub>1</sub>	R <sub>2</sub>
2	Veramivirine	H	$\beta$ -OH
7	Veramiline	H	H
8	Veramiline 3-glucoside	$\beta$ -D-glucose	H

The two methyl singlets which resonated at  $\delta$  0.71 and 0.98 in the  $^1\text{H}$  NMR spectrum were correlated with the two methyl carbons at  $\delta$  13.2 and 19.2, and were assigned to the 18- and 19-methyl groups. On the other hand, the two methyl doublets at  $\delta$  1.01 ( $J = 7.1$  Hz) and 1.06

Table 2.  $^{13}\text{C}$  NMR spectral data of the isolated alkaloids and related compounds (75.3 MHz,  $\text{CDCl}_3$ - $\text{CD}_3\text{OD}$ , 1:1)

C	1	3	4*	2†	8‡
1	37.4	36.6	37.3	37.0	37.7
2	30.0	30.1	33.0	31.4	29.1
3	71.7	70.7	71.7	71.6	78.5
4	42.5	41.4	42.3	42.2	38.2
5	141.0	140.6	140.8	140.7	140.0
6	121.1	121.1	121.3	121.6	121.1
7	31.8	31.4	31.9	31.4	31.5
8	30.4	30.6	30.7	31.3	31.3
9	50.6	48.8	50.4	49.8	49.6
10	36.8	35.9	36.7	36.3	36.2
11	32.1	32.7	21.3	31.3	21.6
12	69.0	71.9	36.7	75.6	39.3
13	45.5	43.7	45.4	44.3	42.2
14	47.2	42.5	57.2	53.6	56.3
15	21.4	28.1	29.4	20.6	23.7
16	62.1	68.8	68.3	35.1	28.4
17	57.4	52.9	62.2	61.3	51.9
18	62.4	16.7	62.9	13.2	17.8
19	19.2	18.6	19.3	19.2	18.7
20	36.1	36.5	35.9	26.2	42.2
21	18.9	16.7	19.2	16.1	17.4
22	74.4	74.4	73.7	61.8	49.1
23	28.7	28.1	30.5	21.1	27.0
24	32.8	31.1	31.6	29.8	30.9
25	31.5	30.1	31.4	39.6	36.8
26	57.9	60.4	57.7	51.0	51.0
27	19.4	18.9	19.3	19.5	20.6

\*In  $\text{CDCl}_3$ .†In  $\text{CDCl}_3$ , 125.3 MHz.‡In pyridine- $d_5$ , glucose carbons are omitted [12].

( $J = 7.4$  Hz) were correlated with the two methyl carbons at  $\delta$  16.1 and 19.5, and are ascribed to the 21- and 27-methyl groups. These assignments revealed the 22,26-epimincholestane skeleton of this alkaloid [6]. The  $\alpha$ -axial proton H-12 resonating at  $\delta$  4.10 as a *dd* ( $J = 8.8$  and 3.6 Hz) is correlated with a methine carbon at  $\delta$  75.6 and is assigned to C-12 on the basis of a HMQC-correlation spectrum. Further structural confirmation was achieved by a  $^1\text{H}$ - $^{13}\text{C}$  HMBC correlation experiment. The quaternary olefinic C-5, resonating at  $\delta$  140.7 showed  $^3J$ -coupling correlations with the H-1 equatorial multiplet at  $\delta$  1.82 and the C-19 methyl singlet at  $\delta$  0.98. The latter methyl singlet exhibited  $^3J$ -couplings with C-1 at  $\delta$  37.0 and  $^2J$ -correlation with the quaternary C-10 at  $\delta$  36.3. Similar correlations occurred between the C-12 axial proton at  $\delta$  4.10 with C-14 and C-17 at  $\delta$  53.6 and 61.3, respectively. The C-14 at  $\delta$  53.6 displayed  $^3J$ -correlation with the equatorial H-7 ( $\delta$  1.95), H-16 ( $\delta$  1.63), H-17 ( $\delta$  1.43) and H<sub>3</sub>-18 ( $\delta$  0.71) proton signals. The C-21 methyl doublet signal at  $\delta$  1.01 also displayed  $^3J$ -correlations with C-17 and C-22 at  $\delta$  61.3 and 61.8, respectively. On the other hand, the C-27 methyl doublet at  $\delta$  1.06 showed  $^3J$ -correlations to C-24 and C-26 at  $\delta$  29.8 and

51.0, respectively.  $^1\text{H}$ - $^1\text{H}$  COSY, TOCSY and NOESY experiments further confirmed these assignments. Therefore, veramivirine was shown to be 12- $\beta$ -hydroxyveramirine [(22S,25S)]-22,26-epimincholest-5-ene-3 $\beta$ ,12 $\beta$ -diol (2).

## EXPERIMENTAL

**General.** Thermospray LC-MS were recorded on Vestec Model 201 mass spectrometer. NMR were recorded at 300 and 500 MHz for proton and 75 and 125 MHz for carbon; TMS was used as int. standard.

**Plant material.** Dried roots and rhizomes of *V. viride* Ait. (6.5) kg were purchased from Wilcox Drug Company, Boone, U.S.A. Identity was confirmed by comparing transverse sections of root and rhizome with those described in the lit. [13].

**Extraction and isolation.** The dried ethanolic extract (460 g) was dissolved in 10 l of 5% tartaric acid. The pH of the soln was adjusted to 6 and extracted with  $\text{CHCl}_3$ . The dried  $\text{CHCl}_3$  extract (18.6 g) was flash chromatographed using 520 g silica gel (70–230 mesh), starting with cyclohexane-EtOAc-diisopropylamine (20:4:1) then with increasing proportions of EtOAc and diisopropylamine and finally isocratically with 15:8:2 (system I), collecting 100 ml frs. Frs 28–53 obtained by elution with system I were pooled and rechromatographed over silica gel. Elution with cyclohexane-EtOAc-Et<sub>3</sub>N (10:4:1) (system II) afforded two major subfrs. Subfrs 15–16 were repeatedly chromatographed on silica gel using system II to afford rubivirine (1) (27 mg). Subfrs 23–26 were treated similarly to afford veramivirine (2) (18.5 mg).

**Rubivirine (1).** Recrystallized from MeOH as needles, mp 239–241°.  $[\alpha]_D + 28.5$  ( $\text{CHCl}_3$ ;  $c$  0.1). Thermospray-LC-MS:  $m/z$  430  $[\text{M} + \text{H}]^+$ . IR  $\nu_{\text{KBr}} \text{ cm}^{-1}$ : 3460, 1450, 1370 and 1040.

**Veramivirine (2).** Recrystallized from MeOH as needles, mp 229–231°.  $[\alpha]_D - 81$  ( $\text{CHCl}_3$ ;  $c$  0.1). Thermospray LC-MS:  $m/z$  416  $[\text{M} + \text{H}]^+$ . IR  $\nu_{\text{KBr}} \text{ cm}^{-1}$ : 3500, 1460 and 1065.

## REFERENCES

- Korol, B., Zuber, A. V. and Miller, L.D. (1970) *J. Pharm. Sci.* **59**, 1110.
- Fuska, J., Fuskova, A., Vassova, A. and Voticky, Z. (1981) *Neoplasma* **28**, 709.
- Standaert, F. G. and Detwiler, P. B. (1970) *J. Pharmacol. Exp. Ther.* **171**, 223.
- Kupchan, S. M., Zimmerman, J. H. and Afonso, A. (1961) *Lloydia* **1**, 24.
- El Sayed, K. A. (1993) Ph.D. Thesis. Mansoura University, Egypt.
- Agrawal, P. K., Srivastava, S. K. and Gaffield, W. (1991) *Alkaloids: Chemical and Biological Perspectives* (Pelletier, S. W., ed.). Springer, New York.
- Kaneko, K., Tanaka, M., Nakaoka, U., Tanaka, Y., Yoshida, N. and Mitsuhashi, H. (1981) *Phytochemistry* **20**, 327.

8. Kaneko, K., Kawamura, N., Mitsuhashi, H. and Ohsaki, K. (1979) *Chem. Pharm. Bull.* **27**, 2534.
9. Keeler, R. F. (1974) *Phytochemistry* **13**, 2336.
10. Vassova, A., Voticky, Z. and Tomoko, J. (1977) *Collect. Czech. Chem. Commun.* **42**, 3643.
11. Yang, C., Liu, R., Zhou, J., Cui, Z., Ni, F. and Yang, Y. (1987) *Yunnan Zhiwu Yanjiu* **9**, 359 *Chem. Abstr.* (1988) **108**, 147145h.
12. Mizuo, M., Tan, R. X., Zhen, P., Min, Z. D., Munekazu, I. and Toshiyuki, T. (1990) *Phytochemistry* **29**, 359.
13. Youngken, H. W. (1952) *J. Am. Pharm. Assoc. Sci. Ed.* **41**, 356.